Hinge Health, Inc. (HNGE)

Financial Performance & Trajectory

Hinge Health is demonstrating a powerful growth reacceleration, with trailing revenue scaling from $0.48B in Q3 2025 to $0.60B in Q1 2026. This represents a dramatic YoY growth inflection from 23.9% to 53.5%, signaling strong market adoption and likely enterprise contract wins. Gross margins, however, present an interesting tension: after a peak of 96.8% in Q3 2025, margins compressed to ~79.8% in Q1 2026. This decline likely reflects a product mix shift toward hardware-intensive or lower-margin service bundles, which is a common trade-off for scaling in Vertical SaaS. Despite this, the business generates exceptional free cash flow, with FCF margins remaining robust at 28.5%—indicating a capital-light model that converts revenue into cash efficiently even as growth accelerates.

Operational & Go-to-Market (GTM) Efficiency

The Rule of 40 metric is elite, surging from 59.2 in Q3 2025 to 82.0 in Q1 2026. This best-in-class reading confirms that Hinge Health is achieving high growth without sacrificing profitability—a hallmark of a mature, disciplined SaaS operator. While specific NRR and CAC payback data are unavailable, the combination of accelerating revenue and widening margins suggests that R&D and GTM investments are generating outsized returns. The FCF margin consistently above 28% implies that customer acquisition costs are being recovered rapidly, and the company is likely operating with strong unit economics. The absence of churn or retention data is a gap, but the revenue trajectory implies sticky enterprise relationships.

Market Valuation & Sentiment

At 6.8x trailing EV/Revenue (stable across the last three quarters), the market is pricing Hinge Health at a premium that reflects its growth reacceleration and cash generation. This multiple is reasonable given the 53.5% top-line growth and 28.5% FCF margins, placing the company in a "growth at a reasonable price" (GARP) zone. Insider activity shows net selling of ~$1.9M, which is modest and not alarming given the company's stage. The Wall Street consensus is overwhelmingly bullish: 13 Buys, 0 Holds, 0 Sells, with an average price target of $65.82. This implies significant upside from current levels, suggesting analysts expect the growth trajectory and margin profile to sustain or improve further.